• Search History (Register)
  • MeSH Browser
    • Afrikaans
      Albanian
      Arabic
      Armenian
      Basque
      Bengali
      Bulgarian
      Catalan
      Cambodian
      Chinese (Mandarin)
      Chinese (Cantonese)
      Croatian
      Czech
      Danish
      Dutch
      English
      Estonian
      Fiji
      Finnish
      French
      Georgian
      German
      Greek
      Gujarati
      Hebrew
      Hindi
      Hungarian
      Icelandic
      Indonesian
      Irish
      Italian
      Japanese
      Javanese
      Korean
      Latin
      Latvian
      Lithuanian
      Macedonian
      Malay
      Malayalam
      Maltese
      Maori
      Marathi
      Mongolian
      Nepali
      Norwegian
      Persian
      Polish
      Portuguese
      Punjabi
      Quechua
      Romanian
      Russian
      Samoan
      Serbian
      Slovak
      Slovenian
      Spanish
      Swahili
      Swedish
      Tamil
      Tatar
      Telugu
      Thai
      Tibetan
      Tonga
      Turkish
      Ukrainian
      Urdu
      Uzbek
      Vietnamese
      Welsh
      Xhosa
      Apply
    • Adelaide Health Technology Assessment
      Agence d'évaluation des technologies et des modes d'intervention en santé
      Agencia de Evaluacion de Tecnologias Sanitarias
      Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)
      Agencia de Qualitat i Avaluacio Sanitries de Catalunya
      Agency for Care Effectiveness (ACE)
      Agency for Health Technology Assessment and Tariff System
      Agency for Healthcare Research and Quality
      Agenzia Sanitaria e Sociale Regionale (Regional Agency for Health and Social Care)
      All Wales Medicines Strategy Group
      Andalusian Health Technology Assessment Area
      Australian Health Technology Advisory Committee
      Australian Safety and Efficacy Register of New Interventional Procedures-Surgical
      Austrian Institute for Health Technology Assessment
      Basque Office for Health Technology Assessment
      Belgian Health Care Knowledge Centre
      BlueCross BlueShield Association
      British Columbia Office of Health Technology Assessment
      Canadian Agency for Drugs and Technologies in Health
      Canadian Coordinating Office for Health Technology Assessment
      Canadian Task Force on Preventive Health Care
      Canary Health Service
      Cellule Innovation of the AP-HP
      Center for Drug Evaluation
      Center for Medical Technology Assessment
      Center for Outcomes Research and Economic Evaluation for Health
      Centre for Clinical Effectiveness
      Centre for Reviews and Dissemination
      Centre for Technology Assessment at the Swiss Science and Technology Council
      Centre Hospitalier de l'Universite de Montreal
      Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale
      Committee for New Health Technology Assessment
      Conseil d'Evaluation des Technologies de la Santé du Québec
      Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
      Danish Centre for Evaluation and Health Technology Assessment
      Danish Institute for Health Services Research
      ECRI Institute
      European Network for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore
      German Agency for HTA at the German Institute for Medical Documentation and Information
      Gesundheit Osterreich GmbH
      Hannover Medical School, Medizinische Hochschule Hannover
      Haute Autorité de Santé
      HAYES, Inc.
      Health Council of the Netherlands Gezondheidsraad
      Health Information and Quality Authority (HIQA)
      Health Intervention and Technology Assessment Program
      Health Quality Ontario
      Health Sciences Institute in Aragon (IACS)
      Health Services Assessment Collaboration
      Health Services Utilization and Research Commission
      Health Technology Advisory Committee
      Health Technology and Policy Unit
      Health Technology Assessment Section, Ministry of Health Malaysia
      Health Technology Board for Scotland
      Health Technology Reference Group
      Health Technology Wales
      HTA Region Stockholm
      HTA South
      HTA Unit, University of Calgary
      Institut national d'excellence en sante et en services sociaux
      Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)
      Institute for Clinical and Economic Review
      Institute for Clinical Effectiveness and Health Policy
      Institute for Clinical Evaluative Sciences
      Institute for Clinical Systems Improvement
      Institute for Quality and Efficiency in Health Care (IQWiG)
      Institute of Applied Health Sciences
      Institute of Health Economics
      Institute of Health Economics
      Institute of Health Technology Assessment and Research (IETSI)
      Institute of Technology Assessment
      Israel Center for Technology Assessment in Health Care
      L'Agence Nationale d'Accreditation d'Evaluation en Santé
      Ludwig Boltzmann Institute for Health Technology Assessment
      Malaysian Health Technology Assessment
      Malaysian Health Technology Assessment Unit
      Medical Advisory Secretariat
      Medical Services Advisory Committee
      Monash Business School, Monash University (MBS)
      National Authority for Assessment and Accreditation in Healthcare (INEAS)
      National Committee for Technology Incorporation (CONITEC)
      National Evidence-based healthcare Collaborating Agency
      National Institute for Clinical Excellence
      National Institute for Health and Care Excellence
      New Zealand Health Technology Assessment
      New Zealand National Health Committee
      NIHR Health and Social Care Delivery Program
      NIHR Health Services and Delivery Research programme
      NIHR Health Technology Assessment programme
      NIHR Horizon Scanning Centre
      NIHR Public Health Research programme
      Norwegian Institute of Public Health
      Norwegian Institute of Public Health
      Norwegian Medical Products Agency
      Ontario Health
      Penn Medicine Center for Evidence-based Practice
      Quality Improvement Scotland
      Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
      Scottish Health Purchasing Information Centre
      Scottish Health Technologies Group
      Scottish Medicines Consortium (SMC)
      State Health Care Accreditation Agency under the Ministry of Health of the Republic of Lithuania
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swiss Federal Office of Public Health (FOPH)
      Technology Assessment at SickKids
      Technology Assessment Unit of the McGill University Health Centre (MUHC)
      The Danish Health Technology Council
      The Federal Joint Committee
      The HTA Center of the Stockholm County Council/Gotland
      The Italian National Agency for Regional Health Services (Agenas)
      The National Health Care Institute (ZIN, Zorginstituut Nederland)
      The National Health Care Institute (Zorginstituut Nederland)
      The Netherlands Organisation for Health Research and Development
      The Regional Health Technology Assessment Centre
      TNO
      U. S. Congress. Office of Technology Assessment
      Unidad de Evaluacion de Tecnologias Sanitarias
      Unidad de Tecnologias de Salud
      Unit of Health Economics and Technology Assessment in Health Care
      University HealthSystem Consortium
      University of York
      VA Technology Assessment Program
      Washington Singer Press
      Washington State Department of Labor and Industries (WSDLI)
      Wessex Institute for Health Research and Development
      West Midlands Health Technology Assessment Collaboration
      WorkSafeBC
      Apply
    • Afghanistan
      Albania
      Algeria
      Andorra
      Antigua and Barbuda
      Argentina
      Armenia
      Australia
      Austria
      Azerbaijan
      Bahamas
      Bahrain
      Bangladesh
      Barbados
      Belarus
      Belgium
      Belize
      Benin
      Bhutan
      Bolivia
      Bosnia and Herzegovina
      Botswana
      Brazil
      Brunei
      Bulgaria
      Burkina Faso
      Burundi
      Cambodia
      Cameroon
      Canada
      Cape Verde
      Central African Republic
      Chad
      Chile
      China
      Colombia
      Comoros
      Congo
      Costa Rica
      Cote dIvoire
      Croatia
      Cuba
      Cyprus
      Czech Republic
      Denmark
      Djibouti
      Dominica
      Dominican Republic
      East Timor
      Ecuador
      Egypt
      El Salvador
      Equatorial Guinea
      Eritrea
      Estonia
      Ethiopia
      Fiji
      Finland
      France
      Gabon
      Gambia
      Georgia
      Germany
      Ghana
      Greece
      Grenada
      Guatemala
      Guinea
      Guinea-Bissau
      Guyana
      Haiti
      Honduras
      Hong Kong
      Hungary
      Iceland
      India
      Indonesia
      Iran
      Iraq
      Ireland
      Israel
      Italy
      Jamaica
      Japan
      Jordan
      Kazakhstan
      Kenya
      Kiribati
      North Korea
      South Korea
      Kuwait
      Kyrgyzstan
      Laos
      Latvia
      Lebanon
      Lesotho
      Liberia
      Libya
      Liechtenstein
      Lithuania
      Luxembourg
      Macedonia
      Madagascar
      Malawi
      Malaysia
      Maldives
      Mali
      Malta
      Marshall Islands
      Mauritania
      Mauritius
      Mexico
      Micronesia
      Moldova
      Monaco
      Mongolia
      Montenegro
      Morocco
      Mozambique
      Myanmar
      Namibia
      Nauru
      Nepal
      Netherlands
      New Zealand
      Nicaragua
      Niger
      Nigeria
      Norway
      Oman
      Pakistan
      Palau
      Panama
      Papua New Guinea
      Paraguay
      Peru
      Philippines
      Poland
      Portugal
      Puerto Rico
      Qatar
      Romania
      Russia
      Rwanda
      Saint Kitts and Nevis
      Saint Lucia
      Saint Vincent and the Grenadines
      Samoa
      San Marino
      Sao Tome and Principe
      Saudi Arabia
      Senegal
      Serbia and Montenegro
      Seychelles
      Sierra Leone
      Singapore
      Slovakia
      Slovenia
      Solomon Islands
      Somalia
      South Africa
      Spain
      Sri Lanka
      Sudan
      Suriname
      Swaziland
      Sweden
      Switzerland
      Syria
      Taiwan
      Tajikistan
      Tanzania
      Thailand
      Togo
      Tonga
      Trinidad and Tobago
      Tunisia
      Turkey
      Turkmenistan
      Tuvalu
      Uganda
      Ukraine
      United Arab Emirates
      United Kingdom
      United States
      Uruguay
      Uzbekistan
      Vanuatu
      Vatican City
      Venezuela
      Vietnam
      Yemen
      Zambia
      Zimbabwe
      Apply

Welcome to the international HTA database

CSV RIS
Showing [23537 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Palbociclib (breast cancer) - Addendum to Commission A18-63]
2019     National Institute for Health and Care Excellence (NICE) Fluocinolone acetonide intravitreal implant for treating recurrent non-infectious uveitis. NICE technology appraisal guidance 590
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Encorafenib (melanoma) - Addendum to Commission A18-61]
2019     National Institute for Health and Care Excellence (NICE) Letermovir for preventing cytomegalovirus disease after a stem cell transplant. NICE technology appraisal guidance 591
2019     NIHR Health Technology Assessment programme Oral versus intravenous antibiotics for bone and joint infections: the OVIVA non-inferiority RCT
2019     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: Cutaquig, preparation of human immunoglobulins, notice of inclusion on the Liste des produits du système du sang du Québec]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Binimetinib (melanoma) - Addendum to Commission A18-62]
2019     National Institute for Health and Care Excellence (NICE) Brentuximab vedotin for untreated advanced Hodgkin lymphoma (terminated appraisal). NICE technology appraisal guidance 594
2019     National Institute for Health and Care Excellence (NICE) gammaCore for cluster headache. NICE medical technologies guidance 46
2019     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: assessment of the relevance of newborn blood spot screening for biotinidase deficiency (BIOT)]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cabozantinib (hepatocellular carcinoma) - Benefit assessment according to §35a Social Code Book V]
2019     National Institute for Health and Care Excellence (NICE) Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer. NICE technology appraisal guidance 595
2019     NIHR Health Technology Assessment programme Exercise or manual physiotherapy compared with a single session of physiotherapy for osteoporotic vertebral fracture: three-arm PROVE RCT
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Durvalumab (non-small cell lung cancer) - Addendum to Commission A18-69]
2019     National Institute for Health and Care Excellence (NICE) Risankizumab for treating moderate to severe plaque psoriasis. NICE technology appraisal guidance 596
2019     Center for Drug Evaluation (CDE) Assessment of the benefits of community day-care facilities for the physically and mentally handicapped
2019     Institut national d'excellence en sante et en services sociaux (INESSS) [Localized and disseminated stages of Lyme disease: from diagnosis to treatment, report in support of the diagnosis and treatment decision support tools]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ocriplasmin (vitreomacular traction) - Addendum to Commission A18-68]
2019     National Institute for Health and Care Excellence (NICE) Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy. NICE technology appraisal guidance 598
2019     National Institute for Health and Care Excellence (NICE) PICO negative pressure wound dressings for closed surgical incisions. NICE medical technologies guidance 43
2019     Institut national d'excellence en sante et en services sociaux (INESSS) [National medical protocols and associated prescriptions, updated in June 2019: acute exacerbations of chronic obstructive pulmonary disease (AECOPD)]
2019     Agency for Care Effectiveness (ACE) Nintedanib and pirfenidone for treating idiopathic pulmonary fibrosis
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Allogeneic stem cell transplantation in aggressive B-cell non-Hodgkin lymphoma and in T-cell non-Hodgkin lymphoma]
2019     National Institute for Health and Care Excellence (NICE) Sodium zirconium cyclosilicate for treating hyperkalaemia. NICE technology appraisal guidance 599
2019     Institut national d'excellence en sante et en services sociaux (INESSS) [National medical protocols and associated prescriptions, updated in June 2019: urethral discharge]
2019     Agency for Care Effectiveness (ACE) Daptomycin and linezolid for treating vancomycin-resistant enterococci bloodstream infections
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Atezolizumab (urothelial carcinoma, first-line treatment) - Benefit assessment according to §35a Social Code Book V (new scientific findings)]
2019     National Institute for Health and Care Excellence (NICE) Pomalidomide with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal). NICE technology appraisal guidance 602
2019     National Institute for Health and Care Excellence (NICE) Endocuff Vision for assisting visualisation during colonoscopy. NICE medical technologies guidance 45
2019     NIHR Health Technology Assessment programme Exercise- and strategy-based physiotherapy-delivered intervention for preventing repeat falls in people with Parkinson's: the PDSAFE RCT
2019     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: effects of assistance dogs and companion animals on persons with autism spectrum disorder or post-traumatic stress disorder]
2019     Agency for Care Effectiveness (ACE) Omalizumab for treating antihistamine-resistant chronic spontaneous urticaria
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (urothelial carcinoma, first line) - Benefit assessment according to §35a Social Code Book V (new scientific findings)]
2019     National Institute for Health and Care Excellence (NICE) Lenalidomide with bortezomib and dexamethasone for untreated multiple myeloma (terminated appraisal). NICE technology appraisal guidance 603
2019     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: Esperoct (turoctocog alfa pegol) – Hemophilia A, notice of inclusion on the Liste des produits du système du sang du Québec]
2019     Agency for Care Effectiveness (ACE) Vedolizumab for treating ulcerative colitis and Crohn's disease
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Damoctocog alfa (haemophilia A) - Benefit assessment according to §35a Social Code Book V]
2019     National Institute for Health and Care Excellence (NICE) Idelalisib for treating refractory follicular lymphoma. NICE technology appraisal guidance 604
2019     National Institute for Health and Care Excellence (NICE) Curos for preventing infections when using needleless connectors. NICE medical technologies guidance 44
2019     NIHR Health Technology Assessment programme Balance Right in Multiple Sclerosis (BRiMS): a guided self-management programme to reduce falls and improve quality of life, balance and mobility in people with multiple sclerosis
2019     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: assessing the senior care and services continuum, prospects for measurement development]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Fingolimod (multiple sclerosis) - Benefit assessment according to §35a Social Code Book V]
2019     National Institute for Health and Care Excellence (NICE) Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea. NICE technology appraisal guidance 605
2019     Institut national d'excellence en sante et en services sociaux (INESSS) [National medical protocols and associated prescriptions, updated June 2019: palliative care - fever]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Patient-specific blister packaging - rapid report]
2019     National Institute for Health and Care Excellence (NICE) Lanadelumab for preventing recurrent attacks of hereditary angioedema. NICE technology appraisal guidance 606
2019     National Institute for Health and Care Excellence (NICE) Senza spinal cord stimulation system for delivering HF10 therapy to treat chronic neuropathic pain. NICE medical technologies guidance 41
2019     Institut national d'excellence en sante et en services sociaux (INESSS) [Guidelines and standards, updated on May 4th 2020 : guide to preventing and treating chemotherapy or radiotherapy-induced nausea and vomiting in adults]
2019     Agency for Care Effectiveness (ACE) Febuxostat for treating chronic hyperuricaemia in adults with gout
2019     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) Medicinsk teknologivurdering (MTV) af HPV vaccination til drenge
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Abemaciclib (breast cancer; combination with an aromatase inhibitor) - Addendum to Commission A18-72]
2019     Agency for Healthcare Research and Quality (AHRQ) Pharmacologic and nonpharmacologic therapies in adult patients with exacerbation of COPD
2019     National Institute for Health and Care Excellence (NICE) Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease. NICE technology appraisal guidance 607
2019     National Institute for Health and Care Excellence (NICE) Mepilex Border Heel and Sacrum dressings for preventing pressure ulcers. NICE medical technologies guidance 40
2019     NIHR Health Technology Assessment programme Peer-led walking programme to increase physical activity in inactive 60- to 70-year-olds: Walk with Me pilot RCT
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Bedaquiline (pulmonary multidrug-resistant tuberculosis) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2019     National Institute for Health and Care Excellence (NICE) Ibrutinib with rituximab for treating Waldenstrom's macroglobulinaemia (terminated appraisal). NICE technology appraisal guidance 608
2019     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: HemlibraMC (emicizumab) - Hemophilia A, notice of inclusion on the Liste des produits du système du sang du Québec]
2019     Agency for Care Effectiveness (ACE) Ezetimibe and ezetimibe/simvastatin for treating primary hypercholesterolaemia
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Melatonin (sleep disorders) - Benefit assessment according to §35a Social Code Book V]
2019     National Institute for Health and Care Excellence (NICE) Ramucirumab for treating unresectable hepatocellular carcinoma after sorafenib (terminated appraisal). NICE technology appraisal guidance 609
2019     Institut national d'excellence en sante et en services sociaux (INESSS) [National medical protocols and associated prescriptions, updated in July 2019: high blood pressure]
2019     Agency for Care Effectiveness (ACE) Rifaximin for reducing recurrent episodes of overt hepatic encephalopathy
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Doravirine/lamivudine/tenofovir disoproxil (HIV infection) - Benefit assessment according to §35a Social Code Book V]
2019     National Institute for Health and Care Excellence (NICE) Pentosan polysulfate sodium for treating bladder pain syndrome. NICE technology appraisal guidance 610
2019     Health Information and Quality Authority (HIQA) Risk in pregnancy — systematic review of economic literature.
2019     NIHR Health Technology Assessment programme Protocolised non-invasive compared with invasive weaning from mechanical ventilation for adults in intensive care: the Breathe RCT
2019     Institut national d'excellence en sante et en services sociaux (INESSS) [National medical protocols and associated prescriptions, updated in October 2019: lipid-lowering pharmacologic agents]
2019     Agency for Care Effectiveness (ACE) Botulinum toxin A for treating blepharospasm or hemifacial spasm
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ribociclib (breast cancer) - Benefit assessment according to §35a Social Code Book V]
2019     National Institute for Health and Care Excellence (NICE) Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer. NICE technology appraisal guidance 611
2019     Health Information and Quality Authority (HIQA) Budget impact analysis – stratification of clinical risk in pregnancy
2019     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: indications justifying the use of imaging for diagnosing patients with primary or secondary headache]
2019     Agency for Care Effectiveness (ACE) Oral COX-2 inhibitors for treating pain
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Doravirine (HIV infection) - Benefit assessment according to §35a Social Code Book V]
2019     National Institute for Health and Care Excellence (NICE) Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab. NICE technology appraisal guidance 612
2019     Health Information and Quality Authority (HIQA) Systematic review of nutritional screening tools for adult patients in acute hospital settings. Nutrition screening and use of oral nutrition support for adults in the acute care setting
2019     Adelaide Health Technology Assessment (AHTA) Serious adverse events associated with influenza vaccination
2019     Agency for Care Effectiveness (ACE) Ferric carboxymaltose for treating iron deficiency anaemia
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Brigatinib (NSCLC) - Benefit assessment according to §35a Social Code Book V]
2019     National Institute for Health and Care Excellence (NICE) Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema in phakic eyes after an inadequate response to previous therapy. NICE technology appraisal guidance 613
2019     NIHR Health Technology Assessment programme Low-dose oral theophylline combined with inhaled corticosteroids for people with chronic obstructive pulmonary disease and high risk of exacerbations: a RCT
2019     Adelaide Health Technology Assessment (AHTA) Faecal calprotectin testing in patients suspected of inflammatory bowel disease (IBD) presenting to primary care
2019     Agency for Care Effectiveness (ACE) Botulinum toxin A for treating cervical dystonia
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Glycerol phenylbutyrate (urea cycle disorders) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2019     National Institute for Health and Care Excellence (NICE) Cannabidiol with clobazam for treating seizures associated with Dravet syndrome. NICE technology appraisal guidance 614
2019     NIHR Health Technology Assessment programme Vertebral artery stenting to prevent recurrent stroke in symptomatic vertebral artery stenosis: the VIST RCT
2019     Adelaide Health Technology Assessment (AHTA) Immunoglobulin for myasthenia gravis
2019     Agency for Care Effectiveness (ACE) Botulinum toxin A for treating focal spasticity of the upper or lower limbs in children with cerebral palsy
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Abemaciclib (breast cancer; combination with fulvestrant) - Addendum to Commission A18-73]
2019     National Institute for Health and Care Excellence (NICE) Cannabidiol with clobazam for treating seizures associated with Lennox-Gastaut syndrome. NICE technology appraisal guidance 615
2019     Adelaide Health Technology Assessment (AHTA) Immunoglobulin for acquired hypogammaglobulinaemia secondary to haematological malignancies, or post-haemopoietic stem cell transplantation (HSCT)
2019     Institut national d'excellence en sante et en services sociaux (INESSS) [Guidelines and standards: managing the risk of suicide and self-harm among youths living in rehabilitation centres for young persons with adjustment problems]
2019     Agency for Care Effectiveness (ACE) Endothelin receptor antagonists for treating pulmonary arterial hypertension
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Fluticasone furoate/umeclidinium/vilanterol (COPD) - Addendum to Commission A18-79]
2019     National Institute for Health and Care Excellence (NICE) Cladribine for treating relapsing–remitting multiple sclerosis. NICE technology appraisal guidance 616
2019     NIHR Health Services and Delivery Research programme Exploring the impact of patient experience data in acute NHS hospital trusts in England: using Actor-Network Theory to optimise organisational strategies and practices for improving patients' experiences of care
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Mexiletine (myotonia) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lanadelumab - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Enzalutamide (prostate cancer) - Addendum to Commission A18-80]